Collaborative Drug Discovery, Inc., receives grant to continue development of tools for researching tuberculosis

Collaborative Drug Discovery, Inc., and SRI International have received a second grant from the National Institute of Allergy and Infectious Diseases to continue a joint development of an information repository and software to identify novel therapeutics for tuberculosis.

"After successful completion of phase I, where we integrated intensive data mining, curation and computational approaches to suggest biological targets and their small molecule modulators, we now look forward to follow-up studies that will refine and validate our approach," Carolyn Talcott, a program director at the information and computer science division at SRI International, said.

The phase II small business technology transfer research grant will support two years of research with a focus on extending a systems biology-cheminformatics approach to develop molecular mimics and computationally evaluate them for drug efficacy.

Researchers from CDD and SRI will continue research from phase I, expand the scope of the search for lead molecules for TB and develop a software product for bioscience research use. Powerful query and analysis capabilities and links to other drug discovery tools and databases will be provided by the new software.

"We are excited to continue our work on this project, which has already resulted in multiple publicly accessible datasets that include results of experimental assays and information about drug compounds," Sean Ekins, the vice president of science at CDD, said. "We will build upon the demonstrated proof-of-concept to identify more compounds active against tuberculosis to include in the repository."